Actually its 25 years from the date of marketing approval.
Makes for a interesting NPV given the TAM.
Sensitivity analysis for distribution deals will need to include re-occurring revenue from booster shots (circa 6 to 12 months post treatment).
Even at a static 10% y-on-y penetration rate of market means will compound of revenue growth (assuming it defers TKR for 5-10 years)
Actually its 25 years from the date of marketing approval. Makes...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 21.0¢ | 19.5¢ | $80.51K | 398.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 112938 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 4396 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |